Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 5/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132565 | 0.75 | ERN1 (0.33) | HSD17B10CYP3A4HPGDCRHBPCRHR2 | |
| SCHEMBL31729576 | 0.69 | HDAC4 (0.69) | HDAC4CRHBPCRHR2KMT2A | |
| SCHEMBL3389625 | 0.69 | HDAC4 (0.69) | HDAC4CRHBPCRHR2KMT2A | |
| SCHEMBL11809082 | 0.69 | ESR1 (0.43) | PDE7AHSD17B10CYP3A4HPGDCRHBP | |
| SCHEMBL27586088 | 0.67 | AKR1C1 (0.48) | HDAC4PDE7AHSD11B1KMT2A | |
| SCHEMBL3391455 | 0.67 | HDAC4 (0.47) | HDAC4CYP3A4HPGDKMT2A | |
| SCHEMBL9539224 | 0.65 | ALDH1A1 (0.48) | PDE7AHSD17B10CYP3A4HPGDTTR | |
| SCHEMBL70463 | 0.63 | HSD17B10 (0.65) | HSD17B10CYP3A4HPGDCRHBPCRHR2 | |
| SCHEMBL2574718 | 0.63 | HSD17B10 (0.65) | HSD17B10CYP3A4HPGDCRHBPCRHR2 | |
| SCHEMBL27974576 | 0.63 | ESR1 (0.57) | HDAC4HSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221596-A1 | Substtituted aryl oximes | BAYER CROPSCIENCE AG (DE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221596-A1 | Substtituted aryl oximes | CYP1A1, PRDX1, CYP1A2 | HDAC4 3233/4885PDE7A 4147/4885HSD17B10 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.